Ability of Rabeprazole to Prevent Gastric Mucosal Damage From Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype - Uotani, Takahiro; Sugimoto, Mitsushige; Nishino, Masafumi; Kodaira, Chise; Yamade, Mihoko; Sahara, Shu; Yamada, Takanori; Osawa, Satoshi; Sugimoto, Ken; Tanaka, Tatsuo; Umemura, Kazuo; Watanabe, Hiroshi; et al. (Clinical gastroenterology and hepatology, 2012)
Keywords: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; Adult; Anti-Ulcer Agents - administration & dosage; Aryl Hydrocarbon Hydroxylases - genetics; Asian Continental Ancestry Group; Aspirin - administration & dosage; Aspirin - adverse effects; Cardiovascular; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Endoscopy, Gastrointestinal; Female; Gastric Mucosa - pathology; Gastroenterology and Hepatology; Genotype; Humans; Male; Peptic Ulcer - prevention & control; PPI; Rabeprazole; Severity of Illness Index; Stomach; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Treatment Outcome; Young Adult; Stomach; AC; ARU; IM; Cardiovascular; NSAID; PPI; LDA; CYP2C19; GSRS; Drug Interactions; MLS; PG; VN; IPA; RM; PM; modified Lanza score; proton pump inhibitor; inhibition of platelet aggregation; pepsinogen; aspirin reaction unit; S-mephenytoin 4′-hydroxylase; Verify Now system; poor metabolizer; Gastrointestinal Symptom Rating Scale; intermediate metabolizer; rapid metabolizer; low-dose aspirin; aspirin and clopidogrel; nonsteroidal anti-inflammatory drug